LRMR · Insider Trading
Larimar Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by LRMR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | John B. Harlow Jr. | President and COO | A | +50,000 | — |
| 2026-07-08 | Thomas Edward Hamilton | Director | Buy | +50,000 | +$166.89K |
| 2026-05-20 | Jeffrey W Sherman | Director | A | +55,150 deriv. | — |
| 2026-05-20 | Thomas Edward Hamilton | Director | A | +55,150 deriv. | — |
| 2026-05-20 | Jonathan S Leff | Director | A | +55,150 deriv. | — |
| 2026-05-20 | Joseph Truitt | Director | A | +55,150 deriv. | — |
| 2026-05-20 | DEERFIELD MANAGEMENT COMPANY, L.P. | Director | A | +55,150 deriv. | — |
| 2026-05-20 | Frank E Thomas | Director | A | +55,150 deriv. | — |
| 2026-03-02 | Frank E Thomas | Director | Buy | +5,000 | +$25.00K |
| 2026-03-02 | Jeffrey W Sherman | Director | Buy | +5,000 | +$25.00K |
| 2026-03-02 | Thomas Edward Hamilton | Director | Buy | +100,000 | +$500.00K |
| 2026-03-02 | Deerfield Mgmt III, L.P. | Director | Buy | +5,000,000 | +$25.00M |
| 2026-01-27 | Gopi Shankar | Chief Development Officer | A | +25,637 | — |
| 2026-01-27 | Carole Ben-Maimon | President and CEO | A | +100,100 | — |
| 2026-01-27 | Russell Clayton | Chief Medical Officer | A | +25,637 | — |
| 2026-01-27 | Michael Celano | Chief Financial Officer | A | +37,604 | — |
| 2025-08-04 | DEERFIELD PARTNERS, L.P. | Director | Buy | +9,375,000 | +$30.00M |
| 2025-05-15 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director | A | +19,000 deriv. | — |
| 2025-05-14 | Frank E Thomas | Director | A | +19,000 deriv. | — |
| 2025-05-14 | Joseph Truitt | Director | A | +19,000 deriv. | — |
| 2025-05-14 | Jeffrey W Sherman | Director | A | +19,000 deriv. | — |
| 2025-05-14 | Jonathan S Leff | Director | A | +19,000 deriv. | — |
| 2025-05-14 | Thomas Edward Hamilton | Director | A | +19,000 deriv. | — |
| 2025-01-24 | Russell Clayton | Chief Medical Officer | A | +23,306 | — |
| 2025-01-24 | Gopi Shankar | Chief Development Officer | A | +23,306 | — |
| 2025-01-24 | Carole Ben-Maimon | President and CEO | A | +91,000 | — |
| 2025-01-24 | Michael Celano | Chief Financial Officer | A | +34,185 | — |
| 2024-06-03 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director | A | +19,000 deriv. | — |
| 2024-05-31 | Frank E Thomas | Director | A | +19,000 deriv. | — |
| 2024-05-31 | Jeffrey W Sherman | Director | A | +19,000 deriv. | — |
| 2024-05-31 | Thomas Edward Hamilton | Director | Buy | +57,208 | +$500.00K |
| 2024-05-31 | Jonathan S Leff | Director | A | +19,000 deriv. | — |
| 2024-05-31 | Joseph Truitt | Director | A | +19,000 deriv. | — |
| 2024-02-16 | Deerfield Mgmt IV, L.P. | Director | Buy | +4,290,617 | +$37.50M |
| 2024-02-15 | Frank E Thomas | Director | Buy | +2,000 | +$22.00K |
| 2024-01-19 | Russell Clayton | Chief Medical Officer | A | +22,500 | — |
| 2024-01-19 | Michael Celano | Chief Financial Officer | A | +31,250 | — |
| 2024-01-19 | Gopi Shankar | Chief Development Officer | A | +22,500 | — |
| 2024-01-19 | Carole Ben-Maimon | President and CEO | A | +66,125 | — |
| 2023-12-08 | Gopi Shankar | Chief Development Officer | Buy | +5,000 | +$18.66K |
| 2023-10-05 | Jeffrey W Sherman | Director | A | +16,600 deriv. | — |
| 2023-07-18 | Russell Clayton | Chief Medical Officer | A | +180,000 deriv. | — |
| 2023-05-18 | Carole Ben-Maimon | President and CEO | Buy | +5,000 | +$18.52K |
| 2023-05-18 | Michael Celano | Chief Financial Officer | Buy | +5,000 | +$18.63K |
| 2023-05-18 | Joseph Truitt | Director | Buy | +2,750 | +$10.26K |
| 2023-05-11 | Joseph Truitt | Director | A | +8,300 deriv. | — |
| 2023-05-11 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director | A | +8,300 deriv. | — |
| 2023-05-11 | Frank E Thomas | Director | A | +8,300 deriv. | — |
| 2023-05-11 | Jonathan S Leff | Director | A | +8,300 deriv. | — |
| 2023-05-11 | Thomas Edward Hamilton | Director | A | +8,300 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| DEERFIELD PARTNERS, L.P. | Director | 7,321,129 | $18.05M |
| Deerfield Mgmt III, L.P. | Director | 6,207,982 | $15.30M |
| Thomas Edward Hamilton | Director | 874,231 | $2.15M |
| Carole Ben-Maimon | President and CEO | 399,432 | $984.60K |
| Michael Celano | Chief Financial Officer | 215,785 | $531.91K |
| Gopi Shankar | Chief Development Officer | 76,443 | $188.43K |
| Russell Clayton | Chief Medical Officer | 71,443 | $176.11K |
| John B. Harlow Jr. | President and COO | 50,000 | $123.25K |
| Frank E Thomas | Director | 7,000 | $17.25K |
| Jeffrey W Sherman | Director | 5,000 | $12.32K |
| Joseph Truitt | Director | 2,750 | $6.78K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LRMR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.